These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 32896704)

  • 1. Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study.
    Roupie AL; Guedon A; Terrier B; Lahuna C; Jachiet V; Regent A; de Boysson H; Carrat F; Seguier J; Terriou L; Versini M; Queyrel V; Groh M; Benhamou Y; Maurier F; Ledoult E; Clech LL; D'Aveni M; Rossignol J; Galland J; Willems L; Chiche NJ; Peterlin P; Roux-Sauvat M; Parcelier A; Wemeau M; Lambert M; Belizna C; Puechal X; Swiader L; Cohen-Valensi R; Noc V; Dao E; Thepot S; de Frémont GM; Tanguy-Schmidt A; Koka AM; Bussone G; Philipponnet C; Konate A; Cavaille G; Guilpain P; Allain JS; Broner J; Solary E; Ruivard M; de Renzis B; Corm S; Baati N; Schleinitz N; Ponsoye M; Stamatoullas-Bastard A; Ades L; Dellal A; Tchirkov A; Aouba A; Fenaux P; Fain O; Mekinian A;
    Semin Arthritis Rheum; 2020 Oct; 50(5):879-884. PubMed ID: 32896704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic/myeloproliferative neoplasms: a French multicentre retrospective case-control study.
    Péan de Ponfilly-Sotier M; Jachiet V; Benhamou Y; Lahuna C; De Renzis B; Kottler D; Voillat L; Dimicoli-Salazar S; Banos A; Chauveheid MP; Alexandra JF; Grignano E; Liferman F; Laborde M; Broner J; Michel M; Lambotte O; Laribi K; Venon MD; Dussol B; Martis N; Thepot S; Park S; Couret D; Roux-Sauvat M; Terriou L; Hachulla E; Bally C; Galland J; Allain JS; Parcelier A; Peterlin P; Cohen-Bittan J; Regent A; Ackermann F; Le Guen J; Algrin C; Charles P; Daguindau E; Puechal X; Dunogue B; Blanchard-Delaunay C; Beyne-Rauzy O; Grobost V; Schmidt J; Le Gallou T; Dubos-Lascu G; Sonet A; Denis G; Roy-Peaud F; Fenaux P; Adès L; Fain O; Mekinian A;
    Clin Exp Rheumatol; 2022 Jul; 40(7):1336-1342. PubMed ID: 35579092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study.
    Mekinian A; Grignano E; Braun T; Decaux O; Liozon E; Costedoat-Chalumeau N; Kahn JE; Hamidou M; Park S; Puéchal X; Toussirot E; Falgarone G; Launay D; Morel N; Trouiller S; Mathian A; Gombert B; Schoindre Y; Lioger B; De Wazieres B; Amoura Z; Buchdaul AL; Georgin-Lavialle S; Dion J; Madaule S; Raffray L; Cathebras P; Piette JC; Rose C; Ziza JM; Lortholary O; Montestruc F; Omouri M; Denis G; Rossignol J; Nimubona S; Adès L; Gardin C; Fenaux P; Fain O
    Rheumatology (Oxford); 2016 Feb; 55(2):291-300. PubMed ID: 26350487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature review.
    Roupie AL; de Boysson H; Thietart S; Carrat F; Seguier J; Terriou L; Versini M; Queyrel V; Groh M; Benhamou Y; Maurier F; Decaux O; d'Aveni M; Rossignol J; Galland J; Solary E; Willems L; Schleinitz N; Ades L; Dellal A; Samson M; Aouba A; Fenaux P; Fain O; Mekinian A;
    Autoimmun Rev; 2020 Feb; 19(2):102446. PubMed ID: 31838164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
    Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
    Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.
    Triguero A; Xicoy B; Zamora L; Jiménez MJ; García O; Calabuig M; Díaz-Beyá M; Arzuaga J; Ramos F; Medina A; Bernal T; Talarn C; Coll R; Collado R; Chen TH; Borrás J; Brunet S; Marchante I; Marco V; López-Cadenas F; Calbacho M; Simiele A; Cortés M; Cedena MT; Pedreño M; Aguilar C; Pedró C; Fernández M; Stoica C; Ribera JM; Sanz G
    Leuk Res; 2022 May; 116():106836. PubMed ID: 35405632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
    Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
    Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Jachiet V; Moulis G; Hadjadj J; Seguier J; Laribi K; Schleinitz N; Vey N; Sacre K; Godeau B; Beyne-Rauzy O; Bouvet R; Broner J; Brun N; Comont T; Gaudin C; Lambotte O; Le Clech L; Peterlin P; Roy-Peaud F; Salvado C; Versini M; Isnard F; Kahn JE; Gobert D; Adès L; Fenaux P; Fain O; Mekinian A
    Haematologica; 2021 May; 106(5):1414-1422. PubMed ID: 33626866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased cardiovascular comorbidities in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia presenting with systemic inflammatory and autoimmune manifestations.
    Kipfer B; Daikeler T; Kuchen S; Hallal M; Andina N; Allam R; Bonadies N
    Semin Hematol; 2018 Oct; 55(4):242-247. PubMed ID: 30502853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
    Usuki K; Ohtake S; Honda S; Matsuda M; Wakita A; Nawa Y; Takase K; Maeda A; Sezaki N; Yokoyama H; Takada S; Hirano D; Tomikawa T; Sumi M; Yano S; Handa H; Ota S; Fujita H; Fujimaki K; Mugitani A; Kojima K; Kajiguchi T; Fujimoto K; Asou N; Usui N; Ishikawa Y; Katsumi A; Matsumura I; Miyazaki Y; Kiyoi H
    Int J Hematol; 2024 Feb; 119(2):130-145. PubMed ID: 38091231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.
    Beran M; Kantarjian H; O'Brien S; Koller C; al-Bitar M; Arbuck S; Pierce S; Moore M; Abbruzzese JL; Andreeff M; Keating M; Estey E
    Blood; 1996 Oct; 88(7):2473-9. PubMed ID: 8839838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDS/CMML from resource-limited region: Characteristics and comparison to tertiary reference European center.
    Sevoyan A; Mekinian A; Chermat F; Adès L; Ivanyan A; Fenaux P; Hakobyan Y
    Eur J Haematol; 2024 Feb; 112(2):296-300. PubMed ID: 37822035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasculitis in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia: A Report of Two Cases.
    Jacobse J; Sijpkens YWJ; van 't Wout JW; Peters EEM; Vlasveld LT
    J Hematol; 2018 Dec; 7(4):158-162. PubMed ID: 32300432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory disorders associated with trisomy 8-myelodysplastic syndromes: French retrospective case-control study.
    Wesner N; Drevon L; Guedon A; Fraison JB; Trad S; Kahn JE; Aouba A; Gillard J; Ponsoye M; Hanslik T; Gourguechon C; Liozon E; Laribi K; Rossignol J; Hermine O; Adès L; Carrat F; Fenaux P; Mekinian A; Fain O;
    Eur J Haematol; 2019 Jan; 102(1):63-69. PubMed ID: 30218579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
    Beran M; Kantarjian H
    Semin Hematol; 1999 Oct; 36(4 Suppl 8):3-10. PubMed ID: 10622223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asthma and risk of myelodysplastic syndromes: a population-based cohort study.
    Frederiksen H; Farkas DK; Horváth-Puhó E; Nørgaard JM; Nørgaard M; Sørensen HT
    Br J Cancer; 2017 Jan; 116(1):100-102. PubMed ID: 27898660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intractable pruritus in chronic myelomonocytic leukaemia and myelodysplastic syndromes: a case series.
    Ceesay MM; Basu TN; du Vivier A; Mufti GJ
    BMJ Case Rep; 2019 Oct; 12(10):. PubMed ID: 31645386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.
    Weihrauch MR; Staib P; Seiberlich B; Hoffmann M; Diehl V; Tesch H
    Leuk Lymphoma; 2004 Apr; 45(4):699-704. PubMed ID: 15160942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes.
    Montoro J; Gallur L; Merchán B; Molero A; Roldán E; Martínez-Valle F; Villacampa G; Navarrete M; Ortega M; Castellví J; Saumell S; Bobillo S; Bosch F; Valcárcel D
    Ann Hematol; 2018 Aug; 97(8):1349-1356. PubMed ID: 29572561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale.
    Ramadan H; Duong VH; Al Ali N; Padron E; Zhang L; Lancet JE; List AF; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S64-6. PubMed ID: 27521328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.